Form 4: ClearPoint Neuro COO Mazin Sabra Awarded Restricted Stock Units

ClearPoint Neuro's Chief Operating Officer, Mazin Sabra, received 33,210 restricted stock units (RSUs) on March 3, 2025, vesting over a three-year period.

Summary

• Mazin Sabra, Chief Operating Officer of ClearPoint Neuro, Inc., was granted 33,210 restricted stock units (RSUs) on March 3, 2025.
• These RSUs represent a contingent right to receive one share of ClearPoint Neuro common stock per unit.
• The RSUs will vest in three tranches: 20% on March 3, 2026, 40% on March 3, 2027, and the remaining 40% on March 3, 2028.
• A Power of Attorney is attached to the Form 4, authorizing Danilo D'Alessandro to sign on behalf of Mazin Sabra.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. It reflects a standard executive compensation practice, indicating confidence in the company's future performance and aligning management's interests with shareholders.

Positives

• The grant of RSUs aligns the COO's interests with those of the shareholders, incentivizing long-term performance.
• The vesting schedule encourages continued service and commitment from the COO over the next three years.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the RSUs.

Industry Context

Equity compensation, such as RSUs, is a common practice in the biotech and medical device industries to attract and retain key executives and align their interests with those of shareholders. ClearPoint Neuro is using this method to compensate their COO.

Comparison to Industry Standards

• RSU grants are a standard form of executive compensation in the medical device industry.
• Companies like Medtronic, Stryker, and Boston Scientific also utilize RSUs as part of their compensation packages for key executives.
• The vesting schedule of the RSUs (20%, 40%, 40% over three years) is a fairly typical vesting structure.
• The size of the grant should be compared to the overall compensation package and the company's market capitalization to determine its relative significance.

Stakeholder Impact

• Shareholders: The RSU grant aligns the COO's interests with those of shareholders, potentially leading to increased long-term value.
• Employees: The grant may boost employee morale by demonstrating the company's commitment to its leadership team.

Key Dates